Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Akers Biosciences, Inc is a medical instruments & supplies business based in the US. Akers Biosciences shares (AKER) are listed on the NASDAQ and all prices are listed in US Dollars. Akers Biosciences employs 4 staff and has a trailing 12-month revenue of around USD0.00.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Active traders
52-week range | USD$1.65 - USD$6.97 |
---|---|
50-day moving average | USD$3.2509 |
200-day moving average | USD$2.5922 |
Wall St. target price | USD$4 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-0.715 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Revenue TTM | USD$1.6 million |
---|---|
Gross profit TTM | USD$478,747 |
Return on assets TTM | -32.18% |
Return on equity TTM | -55.32% |
Profit margin | 0% |
Book value | $1.958 |
Market capitalisation | USD$44 million |
TTM: trailing 12 months
There are currently 1.6 million Akers Biosciences shares held short by investors – that's known as Akers Biosciences's "short interest". This figure is 16.5% down from 1.9 million last month.
There are a few different ways that this level of interest in shorting Akers Biosciences shares can be evaluated.
Akers Biosciences's "short interest ratio" (SIR) is the quantity of Akers Biosciences shares currently shorted divided by the average quantity of Akers Biosciences shares traded daily (recently around 321659.8019802). Akers Biosciences's SIR currently stands at 5.05. In other words for every 100,000 Akers Biosciences shares traded daily on the market, roughly 5050 shares are currently held short.
However Akers Biosciences's short interest can also be evaluated against the total number of Akers Biosciences shares, or, against the total number of tradable Akers Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akers Biosciences's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Akers Biosciences shares in existence, roughly 100 shares are currently held short) or 0.0975% of the tradable shares (for every 100,000 tradable Akers Biosciences shares, roughly 98 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Akers Biosciences.
Find out more about how you can short Akers Biosciences stock.
We're not expecting Akers Biosciences to pay a dividend over the next 12 months.
Akers Biosciences's shares were split on a 1:24 basis on 24 November 2019. So if you had owned 24 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Akers Biosciences shares – just the quantity. However, indirectly, the new 2300% higher share price could have impacted the market appetite for Akers Biosciences shares which in turn could have impacted Akers Biosciences's share price.
Over the last 12 months, Akers Biosciences's shares have ranged in value from as little as $1.65 up to $6.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akers Biosciences's is 0.3354. This would suggest that Akers Biosciences's shares are less volatile than average (for this exchange).
Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York. .
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.